Retatrutide + MOTS-c Stack: Dosage, Benefits, Side Effects & Schedule

Retatrutide and MOTS-c are sometimes paired in community research protocols because they act through different pathways. However, no controlled human trial has studied the combination, its safety, or whether using both produces better results than either compound alone. Any combined schedule should be treated as community-reported practice, not a clinically proven protocol.

Jump to the dosage and schedule, reconstitution guide, side effects, or results and evidence.

The retatrutide + MOTS-c stack pairs two research compounds that act on different parts of metabolism. Retatrutide is Eli Lilly's investigational triple-receptor agonist. It acts on GLP-1, GIP, and glucagon receptors to reduce appetite, support insulin response, and raise energy use. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Researchers add it to study how cells use fuel during a retatrutide-driven calorie deficit.

The community calls this combo the Metabolic Super Stack, the Elite Metabolic Stack, or simply reta + MOTS-c. Each name means the same two-compound setup. This page explains the idea behind the stack, its separate-vial schedule, the math for both vials, key risks, and how it compares with other retatrutide stacks.

Need broader context on combining peptides? See PepPal's stacking safety guide. For supplier and quality-control sourcing, see the PepPal supplier directory. For a product-level example, read our Peptide Partners retatrutide review, which checks a live listing, public batch records, and Finnrick history. You can also check the current Peptide Partners deal before ordering research supplies.

The retatrutide + MOTS-c stack is a two-compound metabolic research protocol. Retatrutide acts on appetite, insulin response, and energy use. MOTS-c is added to study fuel use inside the cell. The theory is simple: retatrutide helps create the calorie deficit, while MOTS-c may help mitochondria use the fuel made available during that deficit.

This stack brings together two different areas of research: incretin hormones and mitochondrial function. The closest comparison is the cagrilintide + retatrutide stack, which focuses more on appetite control. The Advanced Recomp Stack adds a growth-hormone secretagogue for more direct lean-mass support.

Retatrutide (LY3437943) is a once-weekly triple agonist. It acts on GLP-1, which reduces appetite and slows stomach emptying; GIP, which affects insulin response; and glucagon, which affects energy use and fat release. In the Phase 3 TRIUMPH-4 trial, the 12 mg group lost 28.7% of body weight at 68 weeks, compared with 2.1% for placebo.

MOTS-c is a 16-amino-acid peptide linked to mitochondria. It activates AMPK, an energy-sensing pathway also affected by exercise and metformin. Much of the proposed benefit comes from cell and animal work. The native peptide has no completed human efficacy trial. The closest human data comes from CB4211, a MOTS-c analog tested in a Phase 1a/1b study.

Retatrutide has produced large weight changes in human trials, but it mainly works through hormone receptors. MOTS-c raises a different question: could it help muscle cells and mitochondria use fuel during the calorie deficit? Here is the idea behind pairing them:

Start with the per-compound plan to see how each dose changes. Then use the weekly example to see how the two schedules may fit together. These are research and community patterns, not a tested treatment plan.

There is no standard pre-blended retatrutide + MOTS-c vial. The two compounds have different storage limits after mixing, so they are kept in separate vials. Community protocols use subcutaneous injections for both. Neither compound has a supported oral or sublingual form.

For the full standalone schedule, see the retatrutide protocol. For more MOTS-c schedule options, see the MOTS-c dosage guide.

Community protocols often run retatrutide alone for the first 4 weeks at 1 mg weekly before adding MOTS-c in Week 5. This staged setup makes it easier to track stomach side effects and tell which compound may be causing a new problem. No trial has tested this sequence.

For the full 12- to 104-week retatrutide research timeline, TRIUMPH-6 maintenance design, and evidence limits around planned breaks, read the Retatrutide Cycle Length Guide.

This Retatrutide + MOTS-c dosage chart summarizes the retatrutide weekly titration and MOTS-c pulse dosing patterns shown in the dosing section above.

Each compound is mixed on its own. I cross-checked the tables against the Retatrutide protocol page and MOTS-c protocol page so the dose math stays consistent across the site.

For more vial sizes and the full standalone guide, see the retatrutide protocol.

For more vial sizes and calculations, see the MOTS-c dosage guide.

Retatrutide does most of the work on appetite, insulin response, and energy use. MOTS-c is added to study how cells use fuel during a large calorie deficit. I reviewed the main research on both compounds before breaking down the four possible links below. These links may explain why people pair them, but the stack itself has never been tested.

Retatrutide reduces appetite through GLP-1, affects insulin response through GIP, and raises energy use through glucagon. This can create a large calorie deficit, which may also bring fatigue and lean-mass loss. MOTS-c does not replace protein or resistance training. Researchers add it to study whether its effects on mitochondria and muscle could offer extra support.

MOTS-c activates AMP-activated protein kinase (AMPK), an energy sensor that helps cells change how they use fuel. Retatrutide affects appetite, energy use, and fat release. Researchers pair them in hopes that MOTS-c will help cells use the fuel made available during that process. No trial has shown that adding MOTS-c leads to more fat loss.

The compounds may affect glucose control at different points. Retatrutide acts on the GIP receptor, which affects insulin response. MOTS-c has improved glucose uptake into skeletal muscle in animal models. This possible overlap is one reason people pair them. It is also why low blood sugar is a concern when other glucose-lowering drugs or supplements are used.

Early MOTS-c studies suggest that it may lower myostatin signaling. Myostatin is a protein that limits muscle growth. This could matter when trying to keep muscle during a calorie deficit, but it remains the least proven reason for using the stack. There is no direct human evidence.

MOTS-c is linked to some of the same signals that rise with exercise. In one animal study, old mice given MOTS-c roughly doubled their treadmill time. This does not prove the same result in people. It explains why many community plans place MOTS-c on training days, when fatigue from a calorie deficit may be most noticeable.

Retatrutide alone produced 28.7% average weight loss at the top dose in TRIUMPH-4. MOTS-c is not needed to show that retatrutide can drive weight loss. Researchers consider the stack when the question is about mitochondrial function, fatigue, or lean mass during the deficit. Whether MOTS-c improves any of those outcomes in people remains unknown.

No clinical study has measured the side effects of retatrutide and MOTS-c when used together. Retatrutide has documented stomach and appetite-related effects in clinical trials, while human safety data for native MOTS-c remains limited. Combining them may create risks that cannot be predicted from separate-compound studies.

Human safety data for native MOTS-c is limited. Most findings come from animal studies, while the related analog CB4211 reached a Phase 1 trial. Community users report short-term injection-site redness, fatigue, lightheadedness, and sleep changes. These reports are not clinical evidence and cannot show how often an effect occurs.

No study has measured whether MOTS-c changes retatrutide side effects, whether the pair creates new risks, or how either compound affects the other's action. The risk from long-term combined use is also unknown. Medical review is especially important for anyone with severe stomach disease, type 1 diabetes, a history of pancreatitis, a personal or family history of medullary thyroid cancer, active cancer, or medicines that lower blood sugar.

Retatrutide and MOTS-c are not versions of the same compound. They act through different biological pathways and have very different levels of human evidence.

They appear together in stack discussions because they may address separate parts of metabolic research. That idea has not been confirmed in a controlled combination trial.

Phase 3 TRIUMPH-4 included 445 people and lasted 68 weeks. It reported 28.7% average weight loss at 12 mg and 26.4% at 9 mg, compared with 2.1% for placebo. A 2023 Phase 2 trial reported 24.2% average weight loss at 48 weeks in the 12 mg group. These results tested retatrutide alone. They do not prove what happens when MOTS-c is added.

See the full retatrutide protocol for its standalone research, schedule, and vial math.

The native MOTS-c peptide has no completed human efficacy trial. Animal studies found changes in insulin response in older and high-fat-fed mice. Another animal study found that old mice given MOTS-c ran about twice as long on a treadmill. The closest human data comes from CB4211, a related analog studied in a Phase 1a/1b trial. Animal and analog findings do not prove that native MOTS-c improves human outcomes.

See the full MOTS-c dosage guide for its standalone research and vial math.

No controlled human trial has published weight-loss, body-composition, safety, or metabolic results for a retatrutide and MOTS-c combination.

Before-and-after photos and community reports are anecdotal. They usually cannot separate the effects of retatrutide, MOTS-c, calorie intake, exercise, other compounds, or changes in the research schedule. They should not be treated as controlled evidence.

No controlled human study has tested retatrutide and MOTS-c together. Current discussion of the stack combines findings from separate retatrutide and MOTS-c research programs. That can help explain possible mechanisms, but it cannot establish the safety, effectiveness, or ideal schedule of the combination.